Shareholders back charter changes and equity plan at Tandem Diabetes (NASDAQ: TNDM)
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Tandem Diabetes Care, Inc. reported results of its 2026 annual stockholder meeting and related governance changes. Stockholders approved amendments to the Amended and Restated Certificate of Incorporation to allow removal of directors with or without cause and to limit officer liability to the maximum extent permitted by Delaware law.
They also approved an amendment to the 2023 Long-Term Incentive Plan increasing the shares of common stock authorized for issuance under the plan by 3,260,000 shares. All nine director nominees were elected, executive compensation was approved on a non-binding advisory basis, and Ernst & Young LLP was ratified as independent registered public accounting firm for the fiscal year ending December 31, 2026.
There were 68,504,233 shares of common stock outstanding on the March 23, 2026 record date, and 57,964,375 shares were present virtually or by proxy at the meeting, reflecting strong stockholder participation in the governance and compensation decisions.
Positive
- None.
Negative
- None.
8-K Event Classification
4 items: 3.03, 5.02, 5.07, 9.01
4 items
Item 3.03
Material Modification to Rights of Security Holders
Securities
A change was made that materially affects the rights of existing shareholders (e.g., dividend rights, voting rights).
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
LTIP share increase: 3,260,000 shares
Shares outstanding: 68,504,233 shares
Shares present at meeting: 57,964,375 shares
+4 more
7 metrics
LTIP share increase
3,260,000 shares
Additional common shares authorized under 2023 Long-Term Incentive Plan
Shares outstanding
68,504,233 shares
Common stock outstanding on March 23, 2026 record date
Shares present at meeting
57,964,375 shares
Common stock present virtually or by proxy at 2026 annual meeting
Votes for director removal amendment
57,818,029 shares
Proposal 4 to allow director removal with or without cause
Votes for officer exculpation amendment
45,926,405 shares
Proposal 5 limiting officer liability and updating charter
Votes for auditor ratification
57,493,084 shares
Ratification of Ernst & Young LLP for fiscal year ending December 31, 2026
Say-on-pay support
53,460,747 shares for
Non-binding advisory vote on executive compensation
Key Terms
Amended and Restated Certificate of Incorporation, Section 141(k) of the Delaware General Corporation Law, Section 102(b)(7) of the DGCL, non-binding, advisory basis, +2 more
6 terms
Amended and Restated Certificate of Incorporation regulatory
"approved amendments to the Company’s Amended and Restated Certificate of Incorporation to: (i) provide for removal of directors"
A company’s amended and restated certificate of incorporation is an updated version of its foundational legal charter that replaces the older document and folds in all changes into one clear copy; it spells out corporate structure, classes of stock, shareholder rights and key governance rules. Investors care because it can change who controls the company, how votes are counted, what claims shareholders have on assets or dividends, and can introduce or remove protections against takeovers—like updating a house title after a major renovation to show who owns what and under what rules.
Section 141(k) of the Delaware General Corporation Law regulatory
"provide for removal of directors with or without cause, as required by Section 141(k) of the Delaware General Corporation Law"
Section 102(b)(7) of the DGCL regulatory
"limit the liability of officers of the Company to the maximum extent permitted by law as permitted pursuant to Section 102(b)(7) of the DGCL"
non-binding, advisory basis financial
"To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers"
broker non-votes financial
"For | Against | Abstain | Broker Non-Votes 53,460,747 | 1,481,027 | 43,520 | 2,979,081"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
FAQ
What governance changes did Tandem Diabetes Care (TNDM) stockholders approve at the 2026 annual meeting?
Stockholders approved charter amendments allowing removal of directors with or without cause and limiting officer liability to the maximum extent permitted by Delaware law. These changes align the company’s charter with updated provisions of the Delaware General Corporation Law and clarify director and officer protections.
How did Tandem Diabetes Care (TNDM) change its 2023 Long-Term Incentive Plan?
Stockholders approved an amendment to the 2023 Long-Term Incentive Plan increasing shares of common stock authorized for issuance under the plan by 3,260,000 shares. The Board had previously approved the amendment, subject to stockholder approval, to support ongoing equity-based compensation programs.
Were Tandem Diabetes Care (TNDM) director nominees elected at the 2026 annual meeting?
Yes, nine directors were elected to one-year terms expiring at the 2027 annual meeting. Each nominee received a majority of votes cast, with broker non-votes reported separately, confirming continued stockholder support for the company’s current board composition and leadership structure.
Did Tandem Diabetes Care (TNDM) stockholders approve executive compensation on a say-on-pay basis?
Yes, stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. The vote totaled 53,460,747 shares for, 1,481,027 against, and 43,520 abstentions, with 2,979,081 broker non-votes recorded on this advisory compensation proposal.
Who is Tandem Diabetes Care’s (TNDM) independent auditor for fiscal 2026?
Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification vote was 57,493,084 shares for, 454,735 against, and 16,556 abstentions, reflecting broad support for the company’s chosen audit firm.
What was Tandem Diabetes Care’s (TNDM) stockholder participation at the 2026 annual meeting?
There were 68,504,233 shares of common stock outstanding on the March 23, 2026 record date, and 57,964,375 shares were present virtually or represented by proxy. This level of participation provided a strong quorum for voting on directors, compensation, charter amendments, and auditor ratification.